# A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

> **NCT06440005** · PHASE1 · RECRUITING · sponsor: **Angiex, Inc.** · enrollment: 80 (estimated)

## Conditions studied

- Cancer
- Advanced Cancer
- Locally Advanced Carcinoma
- Metastatic Solid Tumor
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Liver Cancer
- Angiosarcoma
- Solid Tumor

## Interventions

- **DRUG:** AGX101

## Key facts

- **NCT ID:** NCT06440005
- **Lead sponsor:** Angiex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-22
- **Primary completion:** 2026-09-06
- **Final completion:** 2027-09-06
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06440005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06440005, "A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06440005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*